Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00000919 · ClinicalTrials.gov registry record · NA

A Study to Evaluate Various Combinations of Anti-HIV Medications to Treat Early HIV Infection

A NA study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Completed
Registry status
NA
Development phase
900
Enrollment target
20
Study locations

NCT00000919: Completed NA study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

NCT00000919 is a NA study of HIV Infections that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 900 participants, above the 444-participant average among 542 other HIV Infections trials with a reported enrollment target (103% higher). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00000919, a NA study of HIV Infections, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

COMPLETED
Registry status
NA
Development phase
900 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to compare the effectiveness of various combinations of anti-HIV drugs in HIV-positive men and women. Patients receive specific combinations of 3 or 4 of the following 6 drugs: didanosine (ddI), stavudine (d4T) efavirenz (EFV), nelfinavir (NFV), lamivudine (3TC), or zidovudine (ZDV). Anti-HIV therapy is effective in preventing the spread of HIV in the body. However, patients often experience unpleasant side effects and have difficulties following the dosing schedule. This study looks for combinations of anti-HIV drugs ("cocktails") which will be the most effective with the fewest problems.

Conditions Studied

HIV Infections

Interventions

  • DRUG Hydroxyurea
  • DRUG Ritonavir
  • DRUG Indinavir sulfate
  • DRUG Lamivudine/Zidovudine
  • DRUG Abacavir sulfate

Study Locations (20)

California

  • Univ of Southern California / LA County USC Med Ctr - Los Angeles
  • UCLA CARE Ctr - Los Angeles
  • Willow Clinic - Menlo Park
  • Univ of California / San Diego Treatment Ctr - San Diego
  • San Francisco AIDS Clinic / San Francisco Gen Hosp - San Francisco
  • San Francisco Gen Hosp - San Francisco
  • Santa Clara Valley Med Ctr / AIDS Community Rsch Consortium - San Jose
  • Marin County Specialty Clinic - San Rafael
  • San Mateo AIDS Program / Stanford Univ - Stanford
  • Stanford Univ Med Ctr - Stanford
  • Harbor UCLA Med Ctr - Torrance

District of Columbia

  • Georgetown Univ Hosp - Washington D.C.
  • Howard Univ - Washington D.C.

Georgia

  • Emory Univ - Atlanta
  • Emory Hemo Comp Evaluation Clinic / East TN Comp Hemo Ctr - Atlanta

Alabama

  • Univ of Alabama at Birmingham - Birmingham

Colorado

  • Univ of Colorado Health Sciences Ctr - Denver

Florida

  • Univ of Miami School of Medicine - Miami

Hawaii

  • Univ of Hawaii - Honolulu

Illinois

  • Northwestern Univ Med School - Chicago

Trial Details

FieldValue
Enrollment Target 900 participants
Est. Completion 2002-11
Phase NA
National Institute of Allergy and Infectious Diseases (NIAID)

2,006 total trials

What the finished NCT00000919 record still lists

NCT00000919 is an interventional study that assigns participants to a tested intervention. The registered 900 participants enrollment target is mid-sized for trials with a published cap, above the 444-participant average among 542 other HIV Infections trials with a reported enrollment target (103% higher).

The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 5 interventions - of which Hydroxyurea is the first listed.

NCT00000919 names 20 study sites across 8 states, led by California, District of Columbia, Georgia.

Frequently Asked Questions

What is clinical trial NCT00000919 about?

NCT00000919 is a clinical study titled "A Study to Evaluate Various Combinations of Anti-HIV Medications to Treat Early HIV Infection". The purpose of this study is to compare the effectiveness of various combinations of anti-HIV drugs in HIV-positive men and women. Patients receive specific combinations of 3 or 4 of the following 6 drugs: didanosine (ddI), stavudine (d4T) efavirenz (EFV), nelfinavir (NFV), lamivudine (3TC), or zido...

What is the current status of trial NCT00000919?

This trial is currently completed. It is a NA study. The enrollment target is 900 participants. Estimated completion is 2002-11.

What conditions does trial NCT00000919 study?

This clinical trial studies the following conditions: HIV Infections.

What interventions are being tested in trial NCT00000919?

The interventions under investigation include: Hydroxyurea (DRUG), Ritonavir (DRUG), Indinavir sulfate (DRUG), Lamivudine/Zidovudine (DRUG), Abacavir sulfate (DRUG).

Who is sponsoring clinical trial NCT00000919?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00000919 being conducted?

This trial has 20 study locations across Alabama, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00000919's enrollment target sits among peer trials

900 33rd of 542 higher than 510 of 542 other HIV Infections trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02352116 · 900 participants · NA

    Evaluation of Post-PACU Pain Management in Pediatric Surgery

  • NCT02414347 · 900 participants

    F 18 T807 Tau PET Imaging of Alzheimer's Disease

  • NCT02670408 · 900 participants

    Diagnostic and Therapeutic Applications of Microarrays in Heart Transplantation

  • NCT02960022 · 900 participants · Phase 2

    A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Related registry views

Source: ClinicalTrials.gov NCT00000919, the US trial registry maintained by the National Library of Medicine. NCT00000919 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.